DUNEDIN, New Zealand, April 12, 2017 /PRNewswire/ -- Pacific Edge is proud to announce that its recent clinical study on Cxbladder Monitor's clinical performance and utility has been published in the ...

DUNEDIN, New Zealand, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Bladder cancer diagnostics provider, Pacific Edge Diagnostics, has been notified by Novitas1 that the LCD: Biomarkers for Oncology (L35396) ...

The agreement with FedMed Inc has been finalised with Pacific Edge's subsidiary in the USA, Pacific Edge Diagnostics USA (PED USA). The agreement provides FedMed's contracted insurance carriers, third ...

Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) welcomes the release of new research supporting the clinical utility of the company's genomic biomarker test Cxbladder Monitor in the ...

Providers using BxLink can easily access Cxbladder's suite of tests, allowing faster integration of these groundbreaking diagnostics into everyday practice. The platform's advanced capabilities ensure ...

Pacific Edge says a New Zealand study of medical professionals shows they are upbeat about the quality of its bladder cancer test. The Dunedin-based company's Cxbladder product is a non-invasive test ...

Newly published research demonstrates that Cxbladder out performs other non-invasive bladder cancer diagnostics, announced Pacific Edge, Ltd. The new research comparing and ranking four widely used ...

Pacific Edge Signs Agreement Extending Commercial Partnership with MidCentral District Health Board, to Encompass All Cxbladder Tests for Application Across the Clinical Pathway Cancer diagnostics ...

Cancer diagnostics company, Pacific Edge Limited (NZX: PEB) has today launched Cxbladder Resolve, the fourth product in the Cxbladder suite of bladder cancer diagnostic tests. Cxbladder Resolve, a ...

Pacific Edge Limited ( (PFGTF)) has shared an update. Cancer diagnostics firm Pacific Edge has secured the first order for its Cxbladder Triage Plus test from Townsville University Hospital, following ...